Clinical and demographic data
| Participant | Age (yr) | Sex | MS Phenotype | Current Disease-Modifying Therapy | EDSS | Years Since Symptom Onset |
|---|---|---|---|---|---|---|
| 1 | 38 | M | RRMS | None | 1 | <1 |
| 2 | 42 | F | RRMS | Dimethyl fumarate | 1.5 | 5 |
| 3 | 32 | F | RRMS | None | 0 | <1 |
| 4 | 40 | F | RRMS | Interferon β-1a | 3 | 6 |
| 5 | 33 | F | RRMS | Daclizumab | 2 | 15 |
| 6 | 39 | M | SPMS | Autologous stem cell transplant, conditioning with cyclophosphamide and rituximab | 6 | 13 |
Note:—SPMS indicates secondary-progressive MS; EDSS, Expanded Disability Status Scale.